Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,617
Employees2,617
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,617
Employees2,617

INCY Key Statistics

Market cap
21.31B
Market cap21.31B
Price-Earnings ratio
18.18
Price-Earnings ratio18.18
Dividend yield
Dividend yield
Average volume
1.73M
Average volume1.73M
High today
$108.52
High today$108.52
Low today
$103.29
Low today$103.29
Open price
$103.74
Open price$103.74
Volume
2.19M
Volume2.19M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$53.56
52 Week low$53.56

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $107.91. The company's market cap stands at 21.31B, with a P/E ratio of 18.18.

On 2026-02-09, Incyte(INCY) stock moved within a range of $103.29 to $108.52. With shares now at $107.91, the stock is trading +4.5% above its intraday low and -0.6% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 2.19M, versus its average volume of 1.73M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

TipRanks 3d
Incyte price target raised to $110 from $102 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Incyte (INCY) to $110 from $102 and keeps an Overweight rating on the shares. Following...

Simply Wall St 3d
How Investors Are Reacting To Incyte EMA Backing For Zynyz Combo In First-Line Anal Cancer

In late January 2026, Incyte reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Zynyz (re...

How Investors Are Reacting To Incyte EMA Backing For Zynyz Combo In First-Line Anal Cancer
TipRanks 4d
Incyte: Market Overpenalizes Jakafi LOE as Diversified Pipeline and Emerging Franchises Support Buy Rating and $135 Target

Incyte (INCY) has received a new Buy rating, initiated by H.C. Wainwright analyst, Mitchell Kapoor. Claim 50% Off TipRanks Premium Unlock hedge fund-level data...

Analyst ratings

48%

of 29 ratings
Buy
41.4%
Hold
48.3%
Sell
10.3%

More INCY News

TipRanks 4d
Incyte initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Incyte (INCY) with a Buy rating and $135 price target The current share price reflects Jakafi loss of exclusivity concerns...

Simply Wall St 5d
Is Incyte Offering Value After A 36% One Year Share Price Gain

If you are wondering whether Incyte's current share price lines up with its underlying worth, you are not alone. This article is designed to help you connect th...

Is Incyte Offering Value After A 36% One Year Share Price Gain
TipRanks 5d
Tafasitamab-Parsaclisib Trial Termination Tempers Incyte Outlook

Incyte (INCY) announced an update on their ongoing clinical study. Tafasitamab-Parsaclisib Basket Trial Halted A Phase 1b/2a basket trial titled “A Phase 1b/2...

Simply Wall St 7d
Assessing Incyte Valuation After Strong 1 Year Return And Recent Share Price Cooldown

Advertisement Context for Incyte’s recent share performance Incyte (INCY) has been trading quietly. The stock is down around 1% over the past week and past mo...

Assessing Incyte Valuation After Strong 1 Year Return And Recent Share Price Cooldown

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.